



Anexa 2a

VERIFICARE ÎNDEPLINIRE STANDARDE MINIMALE

DA

NU

Director CSUD.....

FIȘA DE VERIFICARE

a îndeplinirii standardelor minimale în vederea obținerii atestatului de abilitare

în cadrul I.O.S.U.D. Universitatea de Medicină și Farmacie "Carol Davila" București

Domeniile de doctorat: Medicină, Farmacie

I. Date despre candidat

Gradul didactic/de cercetare: Conferențiar Universitar

Nume: SURCEL

Prenume: CRISTIAN IULIUS

1. Doctor în științe

DA

NU

Titlul tezei de doctorat: "TRATAMENTUL MINIM INVAZIV AL INCONTINENȚEI URINARE DE EFORT LA FEMEIE"

Ordinul de confirmare: Ordinul M.E.C.T. nr. 4698/14.08.2009
Diploma Seria F, nr. 0001385

II. Date numerice privind îndeplinirea standardelor minimale naționale, conform anexelor nr. 20 și 23 ale Ordinului Ministrului Educației Naționale și Cercetării Științifice nr. 6129/20.12.2016

1. Articole publicate în reviste cotate ISI în calitate de autor principal

Criteriaul	Standard minim	Realizat
Număr articole publicate în reviste cotate ISI în calitate de autor principal	10	13



Criteriu indeplinit:

DA

NU

Lista articolelor ISI publicate în calitate de autor principal: autori, titlu articol, revistă, an, volum, pagini, factor de impact

- AP1. **Surcel C**, Savu C, Chibelean C, Iordache A, Mirvald C, Sinescu I.
COMPARATIVE ANALYSIS OF DIFFERENT SURGICAL PROCEDURES FOR FEMALE STRESS URINARY INCONTINENCE. IS STEM CELL IMPLANTATION THE FUTURE?
Romanian Journal of Morphology and Embryology. 2012;53(1):151-4.
ISSN: 1220-0522 (CNCSIS-A+772-ISI), PMID: 22395514, **Impact factor = 0,620**
<https://rjme.ro/RJME/resources/files/530112151154.pdf>
- AP2. **C. Surcel**, C. Mirvald, Carmen Savu, C. Chibelean, I. Sinescu, Maria Viorica Ștefănescu, M. Ferrara
DATA ANALYSIS WITH APPLICATION IN MEDICINE
Economic Computation and Economic Cybernetics Studies and Research Journal, 2012, vol.2,
ISSN: 1842-0650 (CNCSIS-A+332-ISI), **Impact factor = 0,274**
http://www.ecocyb.ase.ro/22012/Stefanescu%20Viorica%20DA_.pdf
- AP3. Savu C, **Surcel C** , Mirvald C, Gingu C, Hortopan M, Sinescu I.
ATYPICAL PRIMARY TUBERCULOSIS MIMICKING AN ADVANCED PENILE CANCER. CAN WE RELY ON PREOPERATIVE ASSESSMENT?
Romanian Journal of Morphology and Embryology. 2012;53(4):1103-6.
ISSN: 1220-0522 (CNCSIS-A+772-ISI), PMID: 23303041, **Impact factor = 0,620**
<https://rjme.ro/RJME/resources/files/53041211031106.pdf>
- AP4. **Surcel CI**, Sooriakumaran P, Briganti A, De Visschere PJ, et al.
PREFERENCES IN MANAGEMENT OF HIGH-RISK PROSTATE CANCER AMONG UROLOGISTS IN EUROPE: RESULTS OF A WEB-BASED SURVEY
British Journal of Urology International BJUI. 2014 May 6. ISSN: 1464-4096. doi: 10.1111/bju.12796. **Impact factor = 3,533**
<https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bju.12796>
- AP5. **C. Surcel**, C. Mirvald, Pavelescu C, Mihai V, Najjar S, Carmen Savu, I. Sinescu
EVALUATION OF RISK FACTORS FOR BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH HIGH RISK PROSTATE CANCER
Economic Computation and Economic Cybernetics Studies and Research Journal, 2015, vol.4, p.111-125
ISSN: 1842-0650, 0424-267X (CNCSIS-A+332-ISI), **Impact factor = 0,317**
<http://www.ecocyb.ase.ro/nr20154/08%20-%20Cristian%20Surcel,%20C.%20Mirvald.pdf>
- AP6. **Surcel C**, Cristian M, Cristian P, Constantin G, Savu C, Huri E, Sinescu I.
MANAGEMENT OF IDIOPATHIC RETROPERITONEAL FIBROSIS FROM THE UROLOGIST'S PERSPECTIVE
Therapeutic Advances in Urology. Apr. 2015, 7(2): 85-99. ISSN: 1756-2872, **Impact factor = 2,79**
PMID: 25829952. doi: 10.1177/1756287214565637
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372523/pdf/10.1177_1756287214565637.pdf
- AP7. **Surcel CI**, van Oort IM, Sooriakumaran P, Briganti A, De Visschere PJ, Fütterer JJ, Ghadjjar P, Isbarn H, Ost P, van den Bergh RC, Yossepowitch O, Giannarini G, Ploussard G
PROGNOSTIC EFFECT OF NEUROENDOCRINE DIFFERENTIATION IN PROSTATE CANCER: A CRITICAL REVIEW
Urologic Oncology. 2014 Sep 16. [Epub], June 2015, 33(6):265.e1-7
ISSN: 1078-1439, PMID: 25238700. doi: 10.1016/j.urolonc.2014.08.007, **Impact factor = 2,768**
<https://www.sciencedirect.com/science/article/abs/pii/S1078143914002841?via%3Dihub>
- AP8. Tsaur I, Heidegger I, Kretschmer A, Borgmann H, Mirvald C, Gandaglia G, Briganti A, den Bergh R, Tilki D, Ost P, Ploussard G, **Surcel C**.
COMBINING ANTICANCER DRUGS WITH OSTEOPROTECTIVE AGENTS IN PROSTATE CANCER-A CONTEMPORARY UPDATE
Urologic Oncology-Seminars and Original Investigations. Nov. 2018, Vol.36, issue 11, pag.488-498, DOI: 10.1016/j.urolonc.2018.08.016. ISSN: 1873-2496. **Impact factor = 2,863**



<https://www.sciencedirect.com/science/article/abs/pii/S1078143918303363?via%3Dihub>

- AP9. Tsaur I, Heidegger I, Kretschmer A, Borgmann H, Gandaglia G, Briganti A, De Visschere P, Mathieu R, Valerio M, van den Bergh RCN, Ost P, Mirvald C, Tilki D, Ploussard G, **Surcel C**
AGGRESSIVE VARIANTS OF PROSTATE CANCER - ARE WE READY TO APPLY SPECIFIC TREATMENT RIGHT NOW?
Cancer Treatment Reviews, 75:20-26, May 2019; PMID: 31783313, DOI: 10.1016/j.ctrv.2019.03.001
ISSN: 0305-7372. **Impact factor = 8,332**
[https://www.cancertreatmentreviews.com/article/S0305-7372\(19\)30049-0/fulltext](https://www.cancertreatmentreviews.com/article/S0305-7372(19)30049-0/fulltext)
- AP10. Futterer JJ, **Surcel C** (contributed equally as first authors), van den Bergh R, Borgmann H, Briganti A, Gandaglia G, Kretschmer A, Ost P, Sooniakumaran P, Tilki D, Valerio M, Ploussard G, de Visschere P
IMAGING MODALITIES IN SYNCHRONOUS OLIGOMETASTATIC PROSTATE CANCER
World Journal of Urology, 37(12): 2573-2583, Dec. 2019; PMID: 30610359, DOI: 10.1007/s00345-018-2416-2
ISSN: 1433-8726. eISSN: 0724-4983, **Impact factor = 3,217**
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868105/pdf/345_2018_Article_2416.pdf
- AP11. **Surcel C**, Mirvald C, Tsaur I, Borgmann H, Heidegger I, Labanaris AP, Sinescu I, Tilki D, Ploussard G, Briganti A, Montorsi F, Mathieu R, Valerio M, Jinga V, Badescu D, Radavol D, van den Bergh R, Gandaglia G, Kretschmer A
CONTEMPORARY ROLE OF PALLIATIVE CYSTOPROSTATECTOMY OR PELVIC EXENTERATION IN ADVANCED SYMPTOMATIC PROSTATE CANCER
World Journal of Urology, Nov. 2020; PMID: 33135127, DOI: 10.1007/s00345-020-03493-5
ISSN: 1433-8726. eISSN: 0724-4983, **Impact factor = 4,226**
<https://link.springer.com/article/10.1007/s00345-020-03493-5>
- AP12. **Surcel C** ✉, Kretschmer A, Mirvald C, Sinescu I, Heidegger I, Tsaur I.
THE MOLECULAR MECHANISMS RELATED WITH OLIGOMETASTATIC PROSTATE CANCER - IS IT JUST A MATTER OF NUMBERS?
Cancers, MDPI, Feb. 2022, Vol. 14, 766, <https://doi.org/10.3390/cancers14030766>, eISSN: 2072-6694, **Impact factor = 6,639**
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833728/pdf/cancers-14-00766.pdf>
- AP13. **Surcel C**, Najjar S, Lbanaris A, Zugor V, Heidegger I, Sinescu I, Gandaglia G, Kretschmer, Mirvald C ✉
MULTICENTRIC COMPARATIVE ANALYSIS OF RETZIUS VERSUS RETZIUS SPARING ROBOTIC ASSISTED SIMPLE PROSTATECTOMY IN THE MANAGEMENT OF LARGE PROSTATE GLANDS
Scandinavian Journal of Urology, Feb. 2022, 1-7, eISSN: 2072-6694, PMID: 35179101, doi: 10.1080/21681805.2022.2038665, **Impact factor = 1,612**
<https://www.tandfonline.com/doi/abs/10.1080/21681805.2022.2038665?journalCode=isju20>

2. Articole publicate în reviste cotate ISI în calitate de coautor

Criteriul	Standard minim	Realizat
Număr articole publicate în reviste cotate ISI în calitate de coautor	5	35

Criteriu îndeplinit:

DA NU

Lista articolelor ISI publicate în calitate de coautor: autori, titlu articol, revistă, an, volum, pagini, factor de impact



UNIVERSITATEA DE MEDICINĂ ȘI FARMACIE
"CAROL DAVILA" din BUCUREȘTI



- CA1. Sinescu I., C. Chibelean, **C. Surcel**, Maria Viorica Ștefănescu, M. Ferrara
PRINCIPAL COMPONENT ANALYSIS AND CLASSIFICATION WITH APPLICATION IN MEDICINE
Economic Computation and Economic Cybernetics Studies and Research Journal - ECECSRJ, 2009, vol.4, 16 pag.
ISSN: 1842-0650 (CNCSIS-A+332-ISI), **Impact factor = 0,247**
- CA2. Gingu C., Ana Moise, Ileana Constantinescu, B. Șerbănescu, **C. Surcel**, I. Sinescu
CYTOTOXIC ANTIBODIES MONITORING IN KIDNEY TRANSPLANTATION – THEIR CLINICAL RELEVANCE AND CHALLENGES
Romanian Journal of Morphology and Embyology, 2012, 53(3): 515-9. ISSN: 1220-0522 (CNCSIS-A+772-ISI), PMID: 22990541,
Impact factor = 0,620
- CA3. Huri E., **C. Surcel**, S. Larre, R. Miano, J. Sorget
INTERNATIONAL YOUNG UROLOGICAL ASSOCIATION: A GLOBAL PLATFORM NETWORK FOR YOUNG UROLOGISTS
Canadian Journal of Urology. 20(4):2013: 6878-6879. ISSN: 1195-9479., PMID: 23930618, **Impact factor = 0,905**
- CA4. Colombel M, Heidenreich A, Martinez-Piñeiro L, Babjuk M, Korneyev I, **Surcel C**, Yakovlev P, Colombo R, et al.
PERIOPERATIVE CHEMOTHERAPY IN MUSCLE-INVASIVE BLADDER CANCER: OVERVIEW AND THE UNMET CLINICAL NEED FOR ALTERNATIVE ADJUVANT THERAPY AS STUDIED IN THE MAGNOLIA TRIAL
European Urology. 2014 Mar;65(3):509-11. ISSN: 0302-2838, PMID: 24268503. doi: 10.1016/j.eururo.2013.10.056.
Impact Factor = 13,938
- CA5. Ploussard G, Isbarn H, Briganti A, Sooriakumaran P, **Surcel C**, Salomon L, Freschi M, Mirvald C, van der Poel HG, Jenkins A, Ost P, van Oort IM, Yossepowitch O, Giannarini G, van den Bergh RC
CAN WE EXPAND ACTIVE SURVEILLANCE CRITERIA TO INCLUDE BIOPSY GLEASON 3+4 PROSTATE CANCER? A MULTI-INSTITUTIONAL STUDY OF 2,323 PATIENTS
Urologic Oncology. 2014 Aug 14. [Epub], Feb. 2015, 33(2):71.e1-9, ISSN: 1078-1439. PMID: 25131660. doi: 10.1016/j.urolonc.2014.07.007, **Impact factor = 2,768**
- CA6. Ghadjar P., A. Briganti, PJL de Visschere, JJ Futterer, G Giannarini, H Isbarn, P Sooriakumaran, **Ci Surcel**, RCN van den Berg, IM van Oort, O Yossepowitch, G Ploussard
THE ONCOLOGIC ROLE OF LOCAL TRATMENT IN PRIMARY METASTATIC PROSTATE CANCER
World Journal of Urology, Vol.33, issue 6, p. 755-761, Jun. 2015, ISSN: 0724-4983. PMID: 24997127, doi:10.1007/s00345-014-1347-9, **Impact factor = 2,397**
- CA7. Gandaglia G., G. Ploussard, H. Isbarn, N.Suardi, P. J, De Visschere, J.J. Futterer, P. Ghadjar, C. Massard, P. Ost, P. Sooriakumaran, **C. Surcel**, R. C. van der Bergh, F. Montorsi, V.Ficarra, G. Giannarini, A. Briganti
WHAT IS THE OPTIMAL DEFINITION OF MISCLASSIFICATION IN PATIENTS WITH VERY LOW RISK PROSTATE CANCER ELIGIBLE FOR ACTIVE SURVEILLANCE? RESULTS FROM A MULTI- INSTITUTIONAL SERIES
Urologic Oncology – Seminars and Original Investigations. April 2015. 33(4):164.e1-164.e9, ISSN: 1078-1439. PMID: 25620154, doi:10.1016/j.urolonc.2014.12.011, **Impact factor = 2,921**
- CA8. Isbarn H, Briganti B, De Visschere PJ, Fütterer J, Ghadjar P, Giannarini G, Ost P, Ploussard G, Sooriakumaran P, **Surcel C**, Van Oort I, Yossepowitch O, van den Bergh R.
SYSTEMATIC ULTRASOUND GUIDED SATURATION AND TEMPLATE BIOPSY OF THE PROSTATE: INDICATIONS AND ADVANTAGES OF EXTENDED SAMPLING
Archivos Espanoles de Urologia, 2015 Apr. 68(3):296-306, PMID: 25948801. ISSN: 0004-0614. **Impact factor = 0,309**
- CA9. **Surcel C**, Mirvald C.
RADICAL CYSTECTOMY IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER AGED >75 YEARS - IS IT PROHIBITED?
Journal of Gerontology & Geriatric Research, 2016; 5:1, Article ID: 1000273, DOI.org/10.4172/2167-7182.1000273
ISSN: 2167-7182. **Impact factor = 0,640**
- CA10. Bultijnck R., **C. Surcel**, G. Ploussard, A. Briganti, P. De Visschere
PRACTICE PATTERNS COMPARED WITH EVIDENCE-BASED STRATEGIES FOR THE MANAGEMENT OF ANDROGEN DEPRIVATION THERAPY-INDUCED SIDE EFFECTS IN PROSTATE CANCER PATIENTS: RESULTS OF A EUROPEAN WEB-BASED SURVEY
European Urology Focus, 2(5):514-521, Dec. 2016, ISSN: 0724-4983, PMID:28723517, DOI: 10.1016/j.euf.2016.02.009,
Impact factor = 0,760



- CA11. De Visschere PJ, Briganti A, Fütterer JJ, Ghadjar P, Isbarn H, Massard C, Ost P, Sooriakumaran P, **Surcel C**, Valerio M, van den Bergh RC, Ploussard G, Giannarini G, Villeirs GM
ROLE OF MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING IN EARLY DETECTION OF PROSTATE CANCER
Insights into Imaging, 2016; Apr; 7(2):205-214. ISSN: 1869-4101. PMID: PMC4805618. Doi: 10.1007/s13244-016-0466-9,
Impact factor = 3,01
- CA12. Bagcioglu M, **C. Surcel**, Ozcan S, Mirvald C, Karagoz MA, Karadag MA, Huri E, Sarica K
MEDICAL MANAGEMENT IN LOCALLY ADVANCED AND METASTATIC PROSTATE CANCER: DOES CHANGES IN TREATMENT POLICY HAVE ANY SPECIFIC EFFECT ON PSA LEVELS?
Arch Ital Urol Androl, Dec. 2017; ISSN: 1124-3562. DOI: 10.1007/s00345-017-2107-4, PMID: 29086020, Impact factor = 0,827
- CA13. May M, **Surcel C**, Capitanio U, Dell'Oglio P, Klätte T, Shariat S, Ecke T, Wolff I, Vergo D, Mirvald C, et al.
PROGNOSTIC AND DISCRIMINATIVE POWER OF THE 7TH TNM CLASSIFICATION FOR PATIENTS WITH SURGICALLY TREATED PAPILLARY RENAL CELL CARCINOMA: RESULTS OF A MULTI-INSTITUTIONAL VALIDATION STUDY (CORONA SUBTYPE PROJECT)
Scandinavian Journal of Urology, Apr. 2017; 12:1-8, ISSN: 2168-1805. doi: 10.1080/21681805.2017, Impact factor = 1,513
- CA14. Borgmann H., M. Musquera, A. Haferkamp, A Vilaseca, T Klätte, S. F. Shariat, A. Scavuzzo, M. A. Jimenez Rios, I. Wolff, U. Capitanio, P. Dell'Oglio, L. M. Krabbe, E. Herrmann, T. Ecke, D. Vergo, N. Huck, N. Wagener, S. Pahernik, S. Zastrow, M. Wirth, **C. Surcel**, C. Mirvald, K. Prochazkova, G. Hutterer, R. Zigeuner, L. Cindolo, M. Hora, C. G. Stief, M. May, S. D. Brookman-May
PROGNOSTIC SIGNIFICANCE OF FUHRMAN GRADE AND AGE FOR CANCER-SPECIFIC AND OVERALL SURVIVAL IN PATIENTS WITH PAPILLARY RENAL CELL CARCINOMA: RESULTS OF AN INTERNATIONAL MULTI-INSTITUTIONAL STUDY ON 2189 PTS
World Journal of Urology, Dec. 2017, 35(12):1891-1897, ISSN: 1433-8726. PMID: 28836063 DOI: 10.1007/s00345-017-2078-5,
Impact factor = 2,981
- CA15. **ORGAN PRESERVATION IS LESS FREQUENTLY PERFORMED IN WOMEN SURGICALLY TREATED FOR PAPILLARY RENAL CELL CARCINOMA-RESULTS OF A COMPREHENSIVE MULTICENTER STUDY.**
Wolff I, Scavuzzo A, Capitanio U, Klätte T, Shariat SF, Wagener N, Zastrow S, Borgmann H, Krabbe LM, Hutterer G, May M, Brookman-May SD; Collaborative Research On Renal Neoplasms Association (CORONA) and the European Association of Urology (EAU) Young Academic Urologists (YAU) Kidney Cancer Group: Cindolo L, Ecke T, Haferkamp A, Herrmann E, Hohenfellner M, Hora M, Hoschke B, Huck N, Rios MAJ, Mirvald C, Musquera M, Dell'Oglio P, Pahernik S, Prochazkova K, Reynoso-Noverón N, Stief CG, **Surcel C**, Vergo D, Waidelich R, Wirth M, Zigeuner R.
Urology, Nov. 2017; 109:107-114. doi: 10.1016/j.urology.2017.06.042., PMID: 28802570. ISSN: 0090-4295. Impact factor = 2,309
- CA16. Tsaui I, Borgmann H, **C. Surcel**, Ost P, Ploussard G.
AR-V7 PREDICTING TREATMENT RESPONSE IN METASTASIZED PROSTATE CANCER: HAS IT PEAKED?
World Journal of Urology, Jan. 2018; ISSN: 1433-8726. PMID: 29473373, DOI: 10.4081/aiua.2017.4.282, Impact factor = 2,761
- CA17. van den Bergh R. Ost P, **Surcel C**, Valerio M. Fütterer JJ, Gandaglia G, Sooriakumaran P, Tilki D, Tsaui I, Ploussard G,
ARE CLINICAL GUIDELINES DESIGNED ACCORDING TO GUIDELINES? CROSS-SECTIONAL ASSESSMENT OF QUALITY AND TRANSPARENCY OF CLINICAL GUIDELINES IN UROLOGY
World Journal of Urology, 36(9):1489-1494, Sep. 2018; ISSN: 1433-8726. PMID: 29610962, DOI: 10.1007/s00345-018-2278-7
Impact factor = 2,761
- CA18. Gandaglia G, van den Bergh RC, Tilki D, Fossati N, Ost P, **Surcel C**, Sooriakumaran P, Tsaui I, Valerio M, Kretschmer A, Zaffuto E, Solomon L, Montorsi F, Graefen M, van der Poel H, de la Taille A, Briganti A, Ploussard G
HOW CAN WE EXPAND ACTIVE SURVEILLANCE CRITERIA IN PATIENTS WITH LOW- AND INTERMEDIATE-RISK PROSTATE CANCER WITHOUT INCREASING THE RISK OF MISCLASSIFICATION? DEVELOPMENT OF A NOVEL RISK CALCULATOR
BJU Int. Nov. 2018, 122(5):823-830. ISSN: 1464-4096. PMID: 297721035, doi: 10.1111/bju.14391, Impact factor = 4,524
- CA19. Marra G, Ploussard G, Ost P, de Visschere P, Briganti A, Gandaglia G, Tilki D, **Surcel C**, Tsaui I, van den Bergh R, Kretschmer A, Borgmann H, Gontero P, Ahmed H, Valerio M.
FOCAL THERAPY IN LOCALISED PROSTATE CANCER: REAL-WORLD UROLOGICAL PERSPECTIVE EXPLORED IN A CROSS-SECTIONAL EUROPEAN SURVEY
Urologic Oncology-Seminars and Original Investigations, Dec. 2018, 36(12):488-498, ISSN: 1873-2496.
DOI: 10.1016/j.urolonc.2018.08.013. Impact factor = 2,863



- CA20. Ploussard G, Borgmann H, Briganti A, de Visschere P, Futterer JJ, Gandaglia G, Heidegger I, Kretschmer A, Mathieu R, Ost P, Sooriakumaran P, **Surcel C**, Tilki D, Tsaur I, Valerio M, van den Bergh R.
POSITIVE PRE-BIOPSY MRI: ARE SYSTEMATIC BIOPSIES STILL USEFUL IN ADDITION TO TARGETED BIOPSIES?
World Journal of Urology, 37(2):277-287, Feb. 2019; ISSN: 1433-8726. PMID: 29967944, DOI: 10.1007/s00345-018-02622-5, **Impact factor = 2,761**
- CA21. **CONTROVERSIES IN MR TARGETED BIOPSY: ALONE OR COMBINED, COGNITIVE VERSUS SOFTWARE-BASED FUSION, TRANSRECTAL VERSUS TRANSPERINEAL APPROACH?**
Marra G, Ploussard G, Futterer JJ, Valerio M, de Visschere P, Tsaur I, Tilki D, Ost P, Gandaglia G, van den Bergh R, **Surcel C**, Borgmann H, Kretschmer A, Heidegger I, Briganti A, Mathieu R.
World Journal of Urology, 37(2):243-251, Feb. 2019; ISSN: 1433-8726. PMID: 30610359, DOI: 10.1007/s00345-018-2399-z, **Impact factor = 2,761**
- CA22. Ploussard G, Gandaglia G, Borgmann H, de Visschere P, Heidegger I, Kretschmer A, Mathieu R, **Surcel C**, Tilki D, Tsaur I, Valerio M, van den Bergh R, Ost P, Briganti A
SALVAGE LYMPH NODE DISSECTION FOR NODAL RECURRENT PROSTATE CANCER: A SYSTEMATIC REVIEW
European Urology, 76(4): 493-504, Epub Oct. 2018, Oct. 2019, ISSN: 0302-2838.
PMID: 30391078, DOI: 10.1016/j.eururo.2018.10.041, **Impact factor = 17,298**
- CA23. Heidegger I, Tsaur I, Borgmann H, **Surcel C**, Kretschmer A, Mathieu R, De Visschere P, Valerio M, van den Bergh RCN, Ost P, Tilki D, Gandaglia G, Ploussard G.
HEREDITARY PROSTATE CANCER - PRIMETIME FOR GENETIC TESTING?
Cancer Treatment Reviews, Vol.81, Dec. 2019; ISSN: 0305-7372. PMID: 31783313, DOI: 10.1016/j.ctrv.2019.101927.
Impact factor = 8,332
- CA24. Mulders PFA, Pineiro LM, Heidenreich A, Babjuk M, Colombel M, Colombo R, Radziszewski P, Korneyev I, **Surcel C**, Yakovlev P
ADJUVANT RECMAGE-A3 IMMUNOTHERAPY AFTER CYSTECTOMY FOR MUSCLE-INVASIVE BLADDER CANCER: LESSONS LEARNED FROM THE PHASE 2 MAGNOLIA CLINICAL TRIAL
European Urology Focus, Vol.5, issue 5, p. 849-852, Sep. 2019, ISSN: 2405-4569. PMID: 294777977, DOI: 10.1016/j.euf.2018.02.005, **Impact factor = 3,430**
- CA25. van den Bergh R, Gandaglia G, Tilki D, Borgmann H, Ost P, **Surcel C**, Valerio M, et al.
TRENDS IN RADICAL PROSTATECTOMY RISK GROUP DISTRIBUTION IN A EUROPEAN MULTICENTER ANALYSIS OF 28 572 PATIENTS: TOWARDS TAILORED TREATMENT
European Urology Focus, Vol.5, issue 5, p. 849-852, Sep. 2019, ISSN: 2405-4569. PMID: 2477797,
DOI: 10.1016/j.euf.2018.02.005, **Impact factor = 3,010**
- CA26. Zastrow S, Krabbe LM, Wolf I, Capitanio U, Klätte T, Ecke T, Huck N, Borgman H, Scavuzzo A, Cindolo L, Schips L, **Surcel C**, Mirvald C, Cabo AV, Musquera M, Hutler G, Prochazkova K, Stief C, Wirth M, May M, Brookman-May S.
EXTERNAL VALIDATION OF A POSTOPERATIVE NOMOGRAM FOR THE PREDICTION OF DISEASE-SPECIFIC SURVIVAL IN PATIENTS WITH PAPILLARY RENAL CELL CARCINOMA USING A LARGE MULTICENTER DATABASE
International Journal of Clinical Oncology, 25(1): 145-150, Jan. 2020. ISSN: 1341-9625, eISSN: 1437-7772,
PMID: 31471787, DOI: 10.1007/s10147-019-01530-x, **Impact factor = 2,503**
- CA27. Preisser F, van den Bergh R, Gandaglia G, Ost P, **Surcel C**, Sooriakumaran P, Montorsi F, Graefen M, van der Poel H, de la Taille A, Briganti A, Salomon L, Ploussard G
EFFECT OF EXTENDED PELVIC LYMPH NODE DISSECTION ON ONCOLOGIC OUTCOMES IN PATIENTS WITH D'AMICO INTERMEDIATE AND HIGH-RISK PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY: A MULTI-INSTITUTIONAL STUDY
The Journal of Urology, 203(2): 338-343, Feb. 2020, ISSN: 0022-5347, eISSN: 1527-3792.,
PMID: 31437119, DOI: 10.1097/JU.000000000000504, **Impact factor = 5,647**
- CA28. Gandaglia G, Martici A, ploussard G, Fossati N, Stabile A, De Visschere P, Borgmann H, Heidegger I, Steinkohl F, Kretschmer A, Marra G, Mathieu R, **Surcel C**, et al.
EXTERNAL VALIDATION OF THE 2019 BRIGANTI NOMOGRAM FOR THE IDENTIFICATION OF PROSTATE CANCER PATIENTS WHO SHOULD BE CONSIDERED FOR AN EXTENDED PELVIC LYMPH NODE DISSECTION
European Urology, Aug. 2020, PMID: 32268944, DOI: 10.1016/j.eururo.2020.03.023, ISSN: 0302-2838, **Impact factor = 17,947**
- CA29. Cornford P, Smith E, MacLennan S, Pereira-Azevedo N, Roobol M, Lumen N, Fullwood L, Duncan E, Dunsmore J, Plass K, Ribal M, Knoll T, Bjartell A, Van Poppel H, N'Dow J, Briganti A, et al. - Collaborators: et al., Sinescu I, **Surcel C**, Baston C, Stoica R.I., Olaru V, et al. - Pan-European National Urological Society IMAGINE Collaborative



IMAGINE-IMPACT ASSESSMENT OF GUIDELINES IMPLEMENTATION AND EDUCATION: THE NEXT FRONTIER FOR HARMONISING UROLOGICAL PRACTICE ACROSS EUROPE BY IMPROVING ADHERENCE TO GUIDELINES
European Urology, 29 Oct. 2020, PMID: 33129581, DOI: 10.1016/j.euro.2020.10.011, ISSN: 0302-2838, Impact factor = 17,947

CA30. Isabel Heidegger K, Igor Tsaur, Giancarlo Marra, Veeru Kasivisvanathan, Alexander Kretschmer, Romain Mathieu, Francesco Ceci, Roderick C.N. van den Bergh, Constance Thibault, Derya Tilki, Massimo Valerio, **Christian Surcel**, and Giorgio Gandaglia
A SYSTEMATIC REVIEW OF THE EMERGING ROLE OF IMMUNE CHECKPOINT INHIBITORS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: WILL COMBINATION STRATEGIES IMPROVE EFFICACY?
Eur Urol Oncol. 2020 Nov 23;S2588-9311(20)30175-9. ISSN: 2588-9311, doi: 10.1016/j.euo.2020.10.010, Impact factor = 7,479

CA31. **A REAL-WORLD COMPARISON OF DOCETAXEL VERSUS ABIRATERONE ACETATE FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER**
Tsaur I., Isabel Heidegger, Jasmin Bektic, Mona Kafka, R.C.N. van den Bergh, J.C.B. Hunting, Anita Thomas, M.P. Brandt, T. Höfner, E. Debedde, Constance Thibault, Paola Ermacora, F. Zattoni, Silvia Foti, A. Kretschmer, G. Ploussard, S. Rodler, G. von Amsberg, Derya Tilki, **C. Surcel**, et al., EAU-YAU Prostate Cancer Working Party
Cancer Med, 2021 Sep;10(18):6354-6364. ISSN: 2045-7634, PMID: 34374489, PMID: 34374489, doi: 10.1002/cam4.4184.
Impact factor = 4,452

CA32. Mona Kafka, **C. Surcel**, Isabel Heidegger
RECENT INSIGHTS ON GENETIC TESTING IN PRIMARY PROSTATE CANCER
Mol Diagn & Ther. 2021 Jul;25(4):425-438. ISSN: 1177-1062, PMID: PMC8249272, doi: 10.1007/s40291-021-00529-3.
Impact factor = 3,380

CA33. Alexander Kretschmer, Guillaume Ploussard, Isabel Heidegger, Igor Tsaur, Hendrik Borgmann, **Cristian Surcel**, Romain Mathieu, Pieter de Visschere, Massimo Valerio, RCN van den Bergh, Giancarlo Marra, Constance Thibault, Piet Ost, Giorgio Gandaglia, Derya Tilki
HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ADVANCED PROSTATE CANCER: A SYSTEMATIC REVIEW
Eur Urol Focus. 2021 Jul;7(4):742-751. ISSN: 2405-4569, PMID: 32089495, doi: 10.1016/j.euf.2020.01.017. Impact factor = 5,996

CA34. Surcel C ☒, Najjar S, Lbanaris A, Zugor V, Heidegger I, Sinescu I, Gandaglia G, Kretschmer, Mirvald C
MULTICENTRIC COMPARATIVE ANALYSIS OF RETZIUS VERSUS RETZIUS SPARING ROBOTIC ASSISTED SIMPLE PROSTATECTOMY IN THE MANAGEMENT OF LARGE PROSTATE GLANDS
Scandinavian Journal of Urology, Feb. 2022, 1-7, eISSN: 2072-6694, doi: 10.1080/21681805.2022.2038665, Impact factor = 1,612

CA35. Igor Tsaur, Roderick CN van den Bergh, Timo Soeterik, Anita Thomas, Maximilian P Brandt, Fabio Zattoni, Fabrizio Dal Moro, Alessandro Morlacco, Jeanlou Collavino, Guillaume Ploussard, **Christian Surcel**, Christian Mirvald, Orel Carmona, Barak Rosenzweig, Christian Ruckes, Tatjana Heisinger, Isabel Heidegger, Giorgio Gandaglia, Robert Dotzauer, EAU-YAU Prostate Cancer Working Party
PREDICTORS OF UNFAVORABLE PATHOLOGY IN PATIENTS WITH INCIDENTAL (PT1A-T1B) PROSTATE CANCER
Eur Urol Focus. 2022 Mar; S2405-4569(22)00063-3. ISSN: 2405-4569, PMID: 35317972, doi: 10.1016/j.euf.2022.03.009. IF=5,996

3. Factorul cumulat de impact pentru articolele publicate ca autor principal în reviste cotate ISI (FCIAP)

Criteriul	Standard minim	Realizat
(ISI) Factor cumulat de impact autor principal	10	37,811

Criteriu îndeplinit:

DA NU



4. Indexul Hirsch

Criteriul	Standard minim	Realizat
Index Hirsch	6	11

Criteriu îndeplinit:

DA NU

Confirm prin prezenta că datele menționate mai sus sunt reale și se referă la propria mea activitate profesională și științifică

Data

30.02.2022

Semnătura candidatului